Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Enterprise Value (2020 - 2026)

Silence Therapeutics' Enterprise Value history spans 8 years, with the latest figure at -$85.1 million for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 42.23% to -$85.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$85.1 million, a 42.23% increase, with the full-year FY2025 number at -$85.1 million, up 42.23% from a year prior.
  • Enterprise Value hit -$85.1 million in Q4 2025 for Silence Therapeutics, up from -$122.4 million in the prior quarter.
  • Over the last five years, Enterprise Value for SLN hit a ceiling of -$62.8 million in Q2 2023 and a floor of -$193.8 million in Q1 2024.
  • Historically, Enterprise Value has averaged -$110.3 million across 5 years, with a median of -$99.2 million in 2021.
  • Biggest five-year swings in Enterprise Value: plummeted 658.63% in 2021 and later skyrocketed 42.23% in 2025.
  • Tracing SLN's Enterprise Value over 5 years: stood at -$99.5 million in 2021, then grew by 16.16% to -$83.4 million in 2022, then increased by 19.21% to -$67.4 million in 2023, then tumbled by 118.55% to -$147.3 million in 2024, then skyrocketed by 42.23% to -$85.1 million in 2025.
  • Business Quant data shows Enterprise Value for SLN at -$85.1 million in Q4 2025, -$122.4 million in Q3 2025, and -$186.6 million in Q2 2025.